- Novateur Ventures Participates in Founding and Financing of Epitopea, a New Cancer Therapeutics Company (May 18, 2022)
- Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine (Feb 24. 2022)
- Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type1 Diabetes and Other Chronic Diseases (Oct 1, 2021)
- BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models (Sept 16, 2021)
- Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers (July 7, 2021)
- Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral (prnewswire.com) (June 6, 2021)
- CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet (June 2, 2021)
- Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 (May 26, 2021)
- FDA Grants Bold Therapeutics’ BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer (May 11, 2021)
- Bold Therapeutics’ BOLD-100 Effective In Vitro Against COVID-19 Variants (April 16, 2021)
- Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders (March 15, 2021)
- Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents (March 15, 2021)
- CalciMedica Announces $21 Million Series D Financing- Quark Venture (March 11, 2021)
- CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007 (February 24, 2021)
- Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials (January 6, 2021)
- National Research Council of Canada supports development of 4 COVID-19 therapeutic candidates – Bold Therapeutics, JN Nova Pharma, Laurent Pharmaceuticals & Qu Biologics (December 18, 2020)
- Qu Biologics Completes $8M Financing (December 9, 2020)
- Spiderwort — FDA grants a Breakthrough Device Designation for Spiderwort Spinal Cord Technology (November 12, 2020)
- Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies’ IPO ( November 9, 2020)
- Virogin Biotech Announces Completion of $62 Million in Series C Financing (September 28, 2020)
- Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19 (October 22, 2020)
- Phenomic AI Launches with $6 Million Financing and an AI/ML Platform for Targeting the Tumor Stroma (October 7, 2020)
- Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 (September 29, 2020)
- Kane Biotech and Animalcare to Form Animal Health Company to target Biofilm-Related Ailments (September 28, 2020)
- Bristol Myers Squibb Enters Agreement to Aquire Forbius, Adding Lead TGF-Beta Asset to Portfolio (August 24, 2020)
- Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership ( August 6, 2020)
- Minister Bains announces members of new Industry Strategy Council – Quark Ventures ( June 2, 2020)
- Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D (May 5, 2020)
- Glycovax Pharma develops a vaccine against COVID-19 (April 21, 2020)
- Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs (April 21, 2020)
- Tetra Bio-Pharma Enters into Co-Development Agreement with Boston-based MAKScientific (Feb 27, 2020)
- Chinook Therapeutics obtains worldwide rights from Abbvie to atrasentan with plans to develop for the treatment of kidney diseases (January 10, 2020)
- Aspect Biosystems Announces US $20 Million Series A Financing to Advance Its Leading Platform for 3D Bioprinting of Human Tissue (January 9, 2020)
- adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector (January 9, 2020)
- Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma (December 4, 2019)
- Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Mexico With Alternavida S.A. (December 2, 2019)
- Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis (December 4, 2019)
- Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund (December 4, 2019)
- Mannin Announces $10.1M Grant, Part of $15.65M Investment to Develop New Therapeutics (November 27, 2019)
- Tetra Bio-pharma: FDA Approves Advancement of PPP001 Clinical Trial Previously Discontinued (November 25, 2019)
- Laurent Pharmaceuticals Receives an Additional up to $3M Award from Cystic Fibrosis Foundation (October 31, 2019)
- Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million (September 10, 2019)
- Repare Therapeutics Announces US$82.5 Million Series B Financing (September 4, 2019)
- Chinook Therapeutics raises $65 million Series A financing to advance precision medicines for kidney diseases (August 22, 2019)
- Prevtec Microbia to be Acquired by Elanco (August 1, 2019)
- Caprion Biosciences and HistoGeneX Unite Businesses to Create Global Leader in Immune Monitoring and Biomarker Development (July 31, 2019)
- Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform (December 19, 2018)
- Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim (December 4, 2018)
- Milestone Pharmaceuticals Announces $80 Million Private Financing (October 25)
- Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (September 19)
- CCAB partners with ImmunoBiochem as it launches new co-development strategy to advance early-stage biotech companies (August 21, 2018)
- Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage (July 31, 2018)
- Innovative Targeting Solutions Announces Antibody Research Collaboration with Sanofi (May 1, 2018
- Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND (April 16, 2018)
- Windsor Expansion Helps BioVectra Meet Global Market Demand (April 12, 2018)
- Sanofi to invest €350M in Canadian Vaccine Facility (April 12, 2018)
- Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians’ Health (April 9, 2018)
- Laurent Pharmaceuticals Reaches Agreement with US Cystic Fibrosis Foundation to Increase Development Award to $US5M (March 14, 2018)
- NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound (February 28, 2018)
- Renaissance BioScience Corp. Retains Blair Jordan as Capital Markets Advisor (January 15, 2018)
- KMT Hepatech announces expansion of staff and operations in Edmonton, AB, Canada (December 21, 2017)
- BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion (December 14, 2017)
- Dr. Nancy Braverman: Champion of the AmorChem Knock-Out Event (December 8, 2017)
- KMT Hepatech announces strategic investment from PhoenixBio: KMT will become a subsidiary of PhoenixBio group and expand its operations (November 16, 2017)
- Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria (November 7, 2017)
- enGene named Company of the Year by BIOTECanada (October 31, 2017)
- Appili Received FDA and Health Canada Clearance to Begin Clinical Trials of its Antibiotic Oral Liquid Reformulation (October 30, 2017)
- Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer (July 17, 2017)
- ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017 (June 27, 2017)
- San Diego trade mission to Vancouver announces Phoenix Molecular Designs’ expansion into the USA (June 23, 2017)
- Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy (May 25, 2017)
- Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b (April 19, 2017)
- Human Hepatocytes from Chimeric Mouse for In Vitro Studies (March 8, 2017)
- Sonic Healthcare and Contextual Genomics Broaden Access to Leading Edge Cancer Genomic Testing (January 3, 2017)
- Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Thereapeutics Deals (December 19, 2016)
- Versant Ventures Portfolio Company Turnstone Biologics completes CAD $55.3 million Series B (November 2, 2016)
- KMT Hepatech is named Best for Healthcare R&D Business Development ‐ Canada (November 1, 2016)
- Ceapro Announces the Grand Opening of New Bio-processing Extraction Facility (September 28, 2016)
- Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration (September 28, 2016)
- Soricimed’s SOR-C13 Granted Orphan Drug Designation for Pancreatic Cancer by the U.S. FDA (September 27, 2016)
- Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis (September 19, 2016)
- Innovative Targeting Solutions Announces Collaboration with Johnson & Johnson Innovation to Advance Drug Discovery @ Innovative Targeting Solutions (August 23, 2016)
- Zymeworks and Innovative Targeting Solutions Enter Collaboration and License Agreement to Advance Biotherapeutics Research and Development (August 11, 2016)
- Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes (July 12, 2016)
- Valeant Canada announces an investment of $10 million in Laval facility to increase and secure its export capacity (June 13, 2016)
- Valeant Canada announces an investment of $7 million in its Steinbach, Manitoba facility (June 10, 2016)
- KMT Hepatech to Partner at BIO International Convention (May 30, 2016)
- Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies (April 26, 2016)
- Zymeworks Names Diana Hausman, M.D. Chief Medical Officer (April 26, 2016)
- New partnership accelerates treatments for Chronic Obstructive Pulmonary Disease patients (March 4, 2016)
- 15th Anniversary of uPA-SCID mouse model with highly humanized liver (February 29, 2016)
- Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics (February 16, 2016)
- New Animal Facility for uPA/SCID Mouse Model with Humanized Liver at KMT Hepatech (February 9, 2016)
- Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration (January 19, 2016)
- Zymeworks Announces $61.5 M Financing to Support the Clinical Development of its Pipeline (January 8, 2016)
- Zymeworks and Kairos Therapeutics Enter into Strategic Partnership (January 8, 2016)
BIOTECanada